 | • レポートコード：MRC2Q12-19242 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、モエキシプリルのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 モエキシプリルのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 モエキシプリルの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 モエキシプリルのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのモエキシプリルの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のモエキシプリルの売上および2028年までの予測に焦点を当てています。 モエキシプリルのグローバル主要企業には、Pfizer、Shermco、Avet Pharmaceuticals、Chartwell Pharmaceuticals、Glenmark Pharmaceuticals、Viatris、Teva Pharmaceuticals、UCB Pharmなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 モエキシプリル市場は、タイプとアプリケーションによって区分されます。世界のモエキシプリル市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 7.5Mg、12.5Mg、15Mg、その他 【アプリケーション別セグメント】 高血圧、心不全 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - モエキシプリル製品概要 - タイプ別市場（7.5Mg、12.5Mg、15Mg、その他） - アプリケーション別市場（高血圧、心不全） - 調査の目的 ・エグゼクティブサマリー - 世界のモエキシプリル販売量予測2017-2028 - 世界のモエキシプリル売上予測2017-2028 - モエキシプリルの地域別販売量 - モエキシプリルの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別モエキシプリル販売量 - 主要メーカー別モエキシプリル売上 - 主要メーカー別モエキシプリル価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（7.5Mg、12.5Mg、15Mg、その他） - モエキシプリルのタイプ別販売量 - モエキシプリルのタイプ別売上 - モエキシプリルのタイプ別価格 ・アプリケーション別市場規模（高血圧、心不全） - モエキシプリルのアプリケーション別販売量 - モエキシプリルのアプリケーション別売上 - モエキシプリルのアプリケーション別価格 ・北米市場 - 北米のモエキシプリル市場規模（タイプ別、アプリケーション別） - 主要国別のモエキシプリル市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのモエキシプリル市場規模（タイプ別、アプリケーション別） - 主要国別のモエキシプリル市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のモエキシプリル市場規模（タイプ別、アプリケーション別） - 主要国別のモエキシプリル市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のモエキシプリル市場規模（タイプ別、アプリケーション別） - 主要国別のモエキシプリル市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのモエキシプリル市場規模（タイプ別、アプリケーション別） - 主要国別のモエキシプリル市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer、Shermco、Avet Pharmaceuticals、Chartwell Pharmaceuticals、Glenmark Pharmaceuticals、Viatris、Teva Pharmaceuticals、UCB Pharm ・産業チェーン及び販売チャネル分析 - モエキシプリルの産業チェーン分析 - モエキシプリルの原材料 - モエキシプリルの生産プロセス - モエキシプリルの販売及びマーケティング - モエキシプリルの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - モエキシプリルの産業動向 - モエキシプリルのマーケットドライバー - モエキシプリルの課題 - モエキシプリルの阻害要因 ・主な調査結果 |
Moexipril an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Moexipril is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Moexipril is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Moexipril is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Moexipril include Pfizer, Shermco, Avet Pharmaceuticals, Chartwell Pharmaceuticals, Glenmark Pharmaceuticals, Viatris, Teva Pharmaceuticals and UCB Pharm, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Moexipril manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Moexipril market. Further, it explains the major drivers and regional dynamics of the global Moexipril market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Shermco
Avet Pharmaceuticals
Chartwell Pharmaceuticals
Glenmark Pharmaceuticals
Viatris
Teva Pharmaceuticals
UCB Pharm
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by dosage strength and by application segments based on sales, price, and value for the period 2017-2028.
Moexipril Segment by Dosage Strength
7.5Mg
12.5Mg
15Mg
Other
Moexipril Segment by Application
Hypertension
Heart failure
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Moexipril market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Moexipril, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Moexipril, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Moexipril, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Moexipril sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Moexipril market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Moexipril sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Shermco, Avet Pharmaceuticals, Chartwell Pharmaceuticals, Glenmark Pharmaceuticals, Viatris, Teva Pharmaceuticals and UCB Pharm, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Moexipril in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Moexipril manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Moexipril sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Moexipril Product Introduction
1.2 Market by Dosage Strength
1.2.1 Global Moexipril Market Size Growth Rate by Dosage Strength, 2017 VS 2021 VS 2028
1.2.2 7.5Mg
1.2.3 12.5Mg
1.2.4 15Mg
1.2.5 Other
1.3 Market by Application
1.3.1 Global Moexipril Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hypertension
1.3.3 Heart failure
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Moexipril Sales Estimates and Forecasts 2017-2028
2.2 Global Moexipril Revenue Estimates and Forecasts 2017-2028
2.3 Global Moexipril Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Moexipril Sales by Region
2.4.1 Global Moexipril Sales by Region (2017-2022)
2.4.2 Global Sales Moexipril by Region (2023-2028)
2.5 Global Moexipril Revenue by Region
2.5.1 Global Moexipril Revenue by Region (2017-2022)
2.5.2 Global Moexipril Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Moexipril Sales by Manufacturers
3.1.1 Global Top Moexipril Manufacturers by Sales (2017-2022)
3.1.2 Global Moexipril Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Moexipril in 2021
3.2 Global Moexipril Revenue by Manufacturers
3.2.1 Global Moexipril Revenue by Manufacturers (2017-2022)
3.2.2 Global Moexipril Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Moexipril Revenue in 2021
3.3 Global Moexipril Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Moexipril Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Moexipril Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Dosage Strength
4.1 Global Moexipril Sales by Dosage Strength
4.1.1 Global Moexipril Historical Sales by Dosage Strength (2017-2022)
4.1.2 Global Moexipril Forecasted Sales by Dosage Strength (2023-2028)
4.1.3 Global Moexipril Sales Market Share by Dosage Strength (2017-2028)
4.2 Global Moexipril Revenue by Dosage Strength
4.2.1 Global Moexipril Historical Revenue by Dosage Strength (2017-2022)
4.2.2 Global Moexipril Forecasted Revenue by Dosage Strength (2023-2028)
4.2.3 Global Moexipril Revenue Market Share by Dosage Strength (2017-2028)
4.3 Global Moexipril Price by Dosage Strength
4.3.1 Global Moexipril Price by Dosage Strength (2017-2022)
4.3.2 Global Moexipril Price Forecast by Dosage Strength (2023-2028)
5 Market Size by Application
5.1 Global Moexipril Sales by Application
5.1.1 Global Moexipril Historical Sales by Application (2017-2022)
5.1.2 Global Moexipril Forecasted Sales by Application (2023-2028)
5.1.3 Global Moexipril Sales Market Share by Application (2017-2028)
5.2 Global Moexipril Revenue by Application
5.2.1 Global Moexipril Historical Revenue by Application (2017-2022)
5.2.2 Global Moexipril Forecasted Revenue by Application (2023-2028)
5.2.3 Global Moexipril Revenue Market Share by Application (2017-2028)
5.3 Global Moexipril Price by Application
5.3.1 Global Moexipril Price by Application (2017-2022)
5.3.2 Global Moexipril Price Forecast by Application (2023-2028)
6 North America
6.1 North America Moexipril Market Size by Dosage Strength
6.1.1 North America Moexipril Sales by Dosage Strength (2017-2028)
6.1.2 North America Moexipril Revenue by Dosage Strength (2017-2028)
6.2 North America Moexipril Market Size by Application
6.2.1 North America Moexipril Sales by Application (2017-2028)
6.2.2 North America Moexipril Revenue by Application (2017-2028)
6.3 North America Moexipril Market Size by Country
6.3.1 North America Moexipril Sales by Country (2017-2028)
6.3.2 North America Moexipril Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Moexipril Market Size by Dosage Strength
7.1.1 Europe Moexipril Sales by Dosage Strength (2017-2028)
7.1.2 Europe Moexipril Revenue by Dosage Strength (2017-2028)
7.2 Europe Moexipril Market Size by Application
7.2.1 Europe Moexipril Sales by Application (2017-2028)
7.2.2 Europe Moexipril Revenue by Application (2017-2028)
7.3 Europe Moexipril Market Size by Country
7.3.1 Europe Moexipril Sales by Country (2017-2028)
7.3.2 Europe Moexipril Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Moexipril Market Size by Dosage Strength
8.1.1 Asia Pacific Moexipril Sales by Dosage Strength (2017-2028)
8.1.2 Asia Pacific Moexipril Revenue by Dosage Strength (2017-2028)
8.2 Asia Pacific Moexipril Market Size by Application
8.2.1 Asia Pacific Moexipril Sales by Application (2017-2028)
8.2.2 Asia Pacific Moexipril Revenue by Application (2017-2028)
8.3 Asia Pacific Moexipril Market Size by Region
8.3.1 Asia Pacific Moexipril Sales by Region (2017-2028)
8.3.2 Asia Pacific Moexipril Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Moexipril Market Size by Dosage Strength
9.1.1 Latin America Moexipril Sales by Dosage Strength (2017-2028)
9.1.2 Latin America Moexipril Revenue by Dosage Strength (2017-2028)
9.2 Latin America Moexipril Market Size by Application
9.2.1 Latin America Moexipril Sales by Application (2017-2028)
9.2.2 Latin America Moexipril Revenue by Application (2017-2028)
9.3 Latin America Moexipril Market Size by Country
9.3.1 Latin America Moexipril Sales by Country (2017-2028)
9.3.2 Latin America Moexipril Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Moexipril Market Size by Dosage Strength
10.1.1 Middle East and Africa Moexipril Sales by Dosage Strength (2017-2028)
10.1.2 Middle East and Africa Moexipril Revenue by Dosage Strength (2017-2028)
10.2 Middle East and Africa Moexipril Market Size by Application
10.2.1 Middle East and Africa Moexipril Sales by Application (2017-2028)
10.2.2 Middle East and Africa Moexipril Revenue by Application (2017-2028)
10.3 Middle East and Africa Moexipril Market Size by Country
10.3.1 Middle East and Africa Moexipril Sales by Country (2017-2028)
10.3.2 Middle East and Africa Moexipril Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Shermco
11.2.1 Shermco Corporation Information
11.2.2 Shermco Overview
11.2.3 Shermco Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Shermco Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Shermco Recent Developments
11.3 Avet Pharmaceuticals
11.3.1 Avet Pharmaceuticals Corporation Information
11.3.2 Avet Pharmaceuticals Overview
11.3.3 Avet Pharmaceuticals Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Avet Pharmaceuticals Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Avet Pharmaceuticals Recent Developments
11.4 Chartwell Pharmaceuticals
11.4.1 Chartwell Pharmaceuticals Corporation Information
11.4.2 Chartwell Pharmaceuticals Overview
11.4.3 Chartwell Pharmaceuticals Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Chartwell Pharmaceuticals Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Chartwell Pharmaceuticals Recent Developments
11.5 Glenmark Pharmaceuticals
11.5.1 Glenmark Pharmaceuticals Corporation Information
11.5.2 Glenmark Pharmaceuticals Overview
11.5.3 Glenmark Pharmaceuticals Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Glenmark Pharmaceuticals Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Glenmark Pharmaceuticals Recent Developments
11.6 Viatris
11.6.1 Viatris Corporation Information
11.6.2 Viatris Overview
11.6.3 Viatris Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Viatris Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Viatris Recent Developments
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Corporation Information
11.7.2 Teva Pharmaceuticals Overview
11.7.3 Teva Pharmaceuticals Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Teva Pharmaceuticals Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Teva Pharmaceuticals Recent Developments
11.8 UCB Pharm
11.8.1 UCB Pharm Corporation Information
11.8.2 UCB Pharm Overview
11.8.3 UCB Pharm Moexipril Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 UCB Pharm Moexipril Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 UCB Pharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Moexipril Industry Chain Analysis
12.2 Moexipril Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Moexipril Production Mode & Process
12.4 Moexipril Sales and Marketing
12.4.1 Moexipril Sales Channels
12.4.2 Moexipril Distributors
12.5 Moexipril Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Moexipril Industry Trends
13.2 Moexipril Market Drivers
13.3 Moexipril Market Challenges
13.4 Moexipril Market Restraints
14 Key Findings in The Global Moexipril Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer